Kyverna Therapeutics, Inc.
$11.25
▲
1.14%
2026-04-21 07:48:00
kyvernatx.com
NMS: KYTX
Explore Kyverna Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$600.17 M
Current Price
$11.25
52W High / Low
$13.67 / $1.78
Stock P/E
—
Book Value
$3.85
Dividend Yield
—
ROCE
-65.99%
ROE
-64.67%
Face Value
—
EPS
$-3.42
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
130
Beta
2.64
Debt / Equity
12.5
Current Ratio
7.75
Quick Ratio
7.75
Forward P/E
-3.14
Price / Sales
—
Enterprise Value
$290.85 M
EV / EBITDA
-1.73
EV / Revenue
—
Rating
Strong Buy
Target Price
$29.6
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | CDT Equity Inc. | $3.35 | — | $16.81 M | — | 230.89% | 491.09% | $3,030 / $2.6 | $83.78 |
| 2. | CNS Pharmaceuticals, Inc. | $2.69 | — | $2.06 M | — | -241.26% | -2.96% | $34.8 / $2.06 | $17.25 |
| 3. | Eikon Therapeutics, Inc. | $11.55 | — | $644.25 M | — | -62.8% | -1.25% | $17.4 / $8.58 | $-286.47 |
| 4. | ProKidney Corp. | $2.1 | — | $634.02 M | — | -54.13% | -43.17% | $7.13 / $0.54 | $-7.13 |
| 5. | Immunic, Inc. | $0.95 | — | $124.59 M | — | 1572.16% | -16.53% | $1.51 / $0.51 | $-0.06 |
| 6. | Ocugen, Inc. | $1.85 | — | $606.61 M | — | -307.31% | -7.77% | $2.73 / $0.64 | $-0.04 |
| 7. | Immunome, Inc. | $24.25 | — | $2.79 B | — | -35.12% | -52.09% | $27.65 / $6.96 | $5.61 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -39.28 M | -38.73 M | -44.41 M | -47.41 M | -41.04 M | — |
| Net Profit | -37.8 M | -36.79 M | -42.08 M | -44.63 M | -37.49 M | — |
| EPS in Rs | -0.63 | -0.61 | -0.7 | -0.74 | -0.62 | -0.8 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 7.03 M |
| Operating Profit | -169.83 M | -142.6 M | -62.41 M | -29.38 M |
| Net Profit | -161.31 M | -127.48 M | -60.37 M | -28.89 M |
| EPS in Rs | -2.67 | -2.11 | -1 | -0.48 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 293.83 M | 304.64 M | 75.19 M | 66.92 M |
| Total Liabilities | 61.55 M | 38.06 M | 206.59 M | 140.92 M |
| Equity | 232.28 M | 266.59 M | -131.4 M | -74 M |
| Current Assets | 282.95 M | 290.6 M | 60.66 M | 53.25 M |
| Current Liabilities | 36.49 M | 33.76 M | 19.86 M | 11.95 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -153.71 M | -114.25 M | -52.41 M | -36.11 M |
| Investing CF | 40.02 M | -160.9 M | -8.79 M | -14.1 M |
| Financing CF | 141.17 M | 337.11 M | 58.12 M | 11.88 M |
| Free CF | -154.84 M | -116.45 M | -53.03 M | -36.88 M |
| Capex | -1.13 M | -2.21 M | -0.62 M | -0.77 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | -100% | — |
| Earnings Growth % | -26.54% | -111.17% | -108.93% | — |
| Profit Margin % | — | — | — | -411.29% |
| Operating Margin % | — | — | — | -418.28% |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | -395.4% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.